Zhichao Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Zhichao Li has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Weiren Huang
The First Affiliated Hospital, Shenzhen University; Shenzhen Second People’s Hospital; Medical Innovation Technology Transformation Center of Shenzhen Second People’s Hospital, Institute for Advanced Study, Synthetic Biology Research Center, International Cancer Center of Shenzhen University, Shenzhen, 518039, China
31 shared publications - Yangyang Sun
Shenzhen Second People's Hospital
28 shared publications - Aolin Li
Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China
27 shared publications - Chenguang Wang
CAS Key Laboratory of Quantitative Engineering Biology, Guangdong Provincial Key Laboratory of Synthetic Genomics and Shenzhen Key Laboratory of Synthetic Genomics, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China
27 shared publications - Fei Song
Correspondence to: Prof. Dr. Fei Song, Shenzhen Medical Academy of Research and Translation, The intersection of Qiangxia 1st Road (East) and Yongchuang Road, Guangming District, Shenzhen 518107, Guangdong, China.; Prof. Yue Zhang, Division of Renal Medicine, Peking University Shenzhen Hospital, Peking University, Lianhua Road 1120, Futian District, Shenzhen 518036, Guangdong, China
27 shared publications - Haibo Xu
Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People’s Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, China
27 shared publications
Latest Publications
- Open Access
- 31 July 2026
- Published by Wiley in Advanced Science
- Vol. 13 (58) , e76768
Engineering a 660 nm‐Responsive Optogenetic Inducer of Pyroptosis for Precision Cancer Therapy
Inducing tumor cell pyroptosis represents a promising anticancer strategy; however, uncontrolled pyroptosis not only restricts the production of viral delivery vectors but also poses a risk of systemic damage, thereby limiting the translational application of pyroptosis‐based therapies. The development of genetic tools that enable precise spatiotemporal control over pyroptosis remains challenging. To address this, we developed PyroRACS, a bioorthogonal optogenetic inducer for precise pyroptosis induction. PyroRACS utilizes an engineered red‐light‐activatable Cre‐ON genetic switch (RACS) to drive the expression of the gasdermin D N‐terminal domain, enabling tunable initiation of pyroptosis without relying on endogenous signaling pathways. We validated robust pyroptosis induction by PyroRACS in multiple cell lines. PyroRACS exhibited high controllability by selectively ablating cancer cells in vitro with precise spatiotemporal resolution. Moreover, its superior controllability enabled the production of the adenovirus vector and allowed “all‐in‐one” delivery of PyroRACS. In a tumor‐bearing mouse model, spatially restricted induction of pyroptosis by PyroRACS resulted in effective tumor suppression, with no detectable systemic toxicity observed under the tested conditions. Collectively, PyroRACS provides a novel optogenetic tool for precise manipulation of pyroptosis, facilitating fundamental research and advancing pyroptosis‐based precision oncology therapeutics.
- 31 July 2026
- Published by Wiley in Advanced Science
- Vol. 13 (58) , e76768
Open AccessEngineering a 660 nm‐Responsive Optogenetic Inducer of Pyroptosis for Precision Cancer Therapy
Inducing tumor cell pyroptosis represents a promising anticancer strategy; however, uncontrolled pyroptosis not only restricts the production of viral delivery vectors but also poses a risk of systemic damage, thereby limiting the translational application of pyroptosis‐based therapies. The development of genetic tools that enable precise spatiotemporal control over pyroptosis remains challenging. To address this, we developed PyroRACS, a bioorthogonal optogenetic inducer for precise pyroptosis induction. PyroRACS utilizes an engineered red‐light‐activatable Cre‐ON genetic switch (RACS) to drive the expression of the gasdermin D N‐terminal domain, enabling tunable initiation of pyroptosis without relying on endogenous signaling pathways. We validated robust pyroptosis induction by PyroRACS in multiple cell lines. PyroRACS exhibited high controllability by selectively ablating cancer cells in vitro with precise spatiotemporal resolution. Moreover, its superior controllability enabled the production of the adenovirus vector and allowed “all‐in‐one” delivery of PyroRACS. In a tumor‐bearing mouse model, spatially restricted induction of pyroptosis by PyroRACS resulted in effective tumor suppression, with no detectable systemic toxicity observed under the tested conditions. Collectively, PyroRACS provides a novel optogenetic tool for precise manipulation of pyroptosis, facilitating fundamental research and advancing pyroptosis‐based precision oncology therapeutics.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Hypertension Promotes the Proliferation and Migration of ccRCC Cells by Downregulation of TIMP3 in Tumor Endothelial Cells through the miR-21–5p/TGFBR2/P38/EGR1 Axis
The clinical details of ccRCC samples
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Hypertension Promotes the Proliferation and Migration of ccRCC Cells by Downregulation of TIMP3 in Tumor Endothelial Cells through the miR-21–5p/TGFBR2/P38/EGR1 Axis
The clinical details of ccRCC samples
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig S2 from Hypertension Promotes the Proliferation and Migration of ccRCC Cells by Downregulation of TIMP3 in Tumor Endothelial Cells through the miR-21–5p/TGFBR2/P38/EGR1 Axis
Supplementary Figure 2 shows the efficiency of endothelial cell depletion in immunomagnetic cell separation, and TIMP3-overexpression in HUVECs suppressed the growth of 786O cancer cells implanted in the subcutaneous tissue of nude mice.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig S2 from Hypertension Promotes the Proliferation and Migration of ccRCC Cells by Downregulation of TIMP3 in Tumor Endothelial Cells through the miR-21–5p/TGFBR2/P38/EGR1 Axis
Supplementary Figure 2 shows the efficiency of endothelial cell depletion in immunomagnetic cell separation, and TIMP3-overexpression in HUVECs suppressed the growth of 786O cancer cells implanted in the subcutaneous tissue of nude mice.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig S3 from Hypertension Promotes the Proliferation and Migration of ccRCC Cells by Downregulation of TIMP3 in Tumor Endothelial Cells through the miR-21–5p/TGFBR2/P38/EGR1 Axis
Supplementary Figure 3 shows the expression of TGFB1 and TIMP3 was not correlated in ccRCC,the relative luciferase activity of 3’UTR region of TIMP3 in HUVECs after TGFBR2 knockout or treatment with SB202190, and the validation of EGR1 over-expression and knockdown efficiency.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig S3 from Hypertension Promotes the Proliferation and Migration of ccRCC Cells by Downregulation of TIMP3 in Tumor Endothelial Cells through the miR-21–5p/TGFBR2/P38/EGR1 Axis
Supplementary Figure 3 shows the expression of TGFB1 and TIMP3 was not correlated in ccRCC,the relative luciferase activity of 3’UTR region of TIMP3 in HUVECs after TGFBR2 knockout or treatment with SB202190, and the validation of EGR1 over-expression and knockdown efficiency.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Hypertension Promotes the Proliferation and Migration of ccRCC Cells by Downregulation of TIMP3 in Tumor Endothelial Cells through the miR-21–5p/TGFBR2/P38/EGR1 Axis
Transcription factors that could potentially bind to the promoter region of TIMP3 estimated by HOCOMOCO (A) and JASPAR2018 (B)
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Hypertension Promotes the Proliferation and Migration of ccRCC Cells by Downregulation of TIMP3 in Tumor Endothelial Cells through the miR-21–5p/TGFBR2/P38/EGR1 Axis
Transcription factors that could potentially bind to the promoter region of TIMP3 estimated by HOCOMOCO (A) and JASPAR2018 (B)
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Hypertension Promotes the Proliferation and Migration of ccRCC Cells by Downregulation of TIMP3 in Tumor Endothelial Cells through the miR-21–5p/TGFBR2/P38/EGR1 Axis
Table S2 from Hypertension Promotes the Proliferation and Migration of ccRCC Cells by Downregulation of TIMP3 in Tumor Endothelial Cells through the miR-21–5p/TGFBR2/P38/EGR1 Axis
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Hypertension Promotes the Proliferation and Migration of ccRCC Cells by Downregulation of TIMP3 in Tumor Endothelial Cells through the miR-21–5p/TGFBR2/P38/EGR1 Axis
Table S2 from Hypertension Promotes the Proliferation and Migration of ccRCC Cells by Downregulation of TIMP3 in Tumor Endothelial Cells through the miR-21–5p/TGFBR2/P38/EGR1 Axis
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig S1 from Hypertension Promotes the Proliferation and Migration of ccRCC Cells by Downregulation of TIMP3 in Tumor Endothelial Cells through the miR-21–5p/TGFBR2/P38/EGR1 Axis
Supplementary Figure 1 shows TIMP3 is a favorable prognostic marker in several tumors, and the expression distribution of TIMP3 with age, stage, and blood pressure.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig S1 from Hypertension Promotes the Proliferation and Migration of ccRCC Cells by Downregulation of TIMP3 in Tumor Endothelial Cells through the miR-21–5p/TGFBR2/P38/EGR1 Axis
Supplementary Figure 1 shows TIMP3 is a favorable prognostic marker in several tumors, and the expression distribution of TIMP3 with age, stage, and blood pressure.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Hypertension Promotes the Proliferation and Migration of ccRCC Cells by Downregulation of TIMP3 in Tumor Endothelial Cells through the miR-21–5p/TGFBR2/P38/EGR1 Axis
Differentially expressed genes between ccRCC patients with normal blood pressure and hypertension in bulk RNA-seq (A) and scRNA-seq (B), and Genes with higher expression levels in endothelial cells than other cells (C)
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Hypertension Promotes the Proliferation and Migration of ccRCC Cells by Downregulation of TIMP3 in Tumor Endothelial Cells through the miR-21–5p/TGFBR2/P38/EGR1 Axis
Differentially expressed genes between ccRCC patients with normal blood pressure and hypertension in bulk RNA-seq (A) and scRNA-seq (B), and Genes with higher expression levels in endothelial cells than other cells (C)
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Hypertension Promotes the Proliferation and Migration of ccRCC Cells by Downregulation of TIMP3 in Tumor Endothelial Cells through the miR-21–5p/TGFBR2/P38/EGR1 Axis
Top 100 genes that have similar expression patterns with TIMP3 in ccRCC by GEPIA2
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Hypertension Promotes the Proliferation and Migration of ccRCC Cells by Downregulation of TIMP3 in Tumor Endothelial Cells through the miR-21–5p/TGFBR2/P38/EGR1 Axis
Top 100 genes that have similar expression patterns with TIMP3 in ccRCC by GEPIA2
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Hypertension Promotes the Proliferation and Migration of ccRCC Cells by Downregulation of TIMP3 in Tumor Endothelial Cells through the miR-21–5p/TGFBR2/P38/EGR1 Axis
Recent studies have demonstrated that hypertension correlates with tumorigenesis and prognosis of clear-cell renal cell carcinoma (ccRCC); however, the underlying molecular mechanisms remain unclear. By analyzing bulk and single-cell RNA sequencing data and experimental examining of surgical excised ccRCC samples, we found that tissue inhibitors of metalloproteinases 3 (TIMP3), a pivotal paracrine factor in suppressing tumor progression, was significantly reduced in the tumor endothelial cells of patients with hypertensive ccRCC. Besides, in tumor xenograft of NCG mouse model, compared with saline normotensive group the expression of TIMP3 was significantly decreased in the angiotensin II–induced hypertension group. Treating human umbilical vein endothelial cells (HUVEC) with the plasma of patients with hypertensive ccRCC and miR-21–5p, elevated in the plasma of patients with hypertensive ccRCC, reduced the expression of TIMP3 compared with normotensive and control littermates. We also found that the inhibition of TIMP3 expression by miR-21–5p was not through directly targeting at 3′UTR of TIMP3 but through suppressing the expression of TGFβ receptor 2 (TGFBR2). In addition, the knockout of TGFBR2 reduced TIMP3 expression in HUVECs through P38/EGR1 (early growth response protein 1) signaling axis. Moreover, via coculture of ccRCC cell lines with HUVECs and mouse tumor xenograft model, we discovered that the TIMP3 could suppress the proliferation and migration of ccRCC.Implications:Overall, our findings shed new light on the role of hypertension in promoting the progression of ccRCC and provide a potential therapeutic target for patients with ccRCC with hypertension.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Hypertension Promotes the Proliferation and Migration of ccRCC Cells by Downregulation of TIMP3 in Tumor Endothelial Cells through the miR-21–5p/TGFBR2/P38/EGR1 Axis
Recent studies have demonstrated that hypertension correlates with tumorigenesis and prognosis of clear-cell renal cell carcinoma (ccRCC); however, the underlying molecular mechanisms remain unclear. By analyzing bulk and single-cell RNA sequencing data and experimental examining of surgical excised ccRCC samples, we found that tissue inhibitors of metalloproteinases 3 (TIMP3), a pivotal paracrine factor in suppressing tumor progression, was significantly reduced in the tumor endothelial cells of patients with hypertensive ccRCC. Besides, in tumor xenograft of NCG mouse model, compared with saline normotensive group the expression of TIMP3 was significantly decreased in the angiotensin II–induced hypertension group. Treating human umbilical vein endothelial cells (HUVEC) with the plasma of patients with hypertensive ccRCC and miR-21–5p, elevated in the plasma of patients with hypertensive ccRCC, reduced the expression of TIMP3 compared with normotensive and control littermates. We also found that the inhibition of TIMP3 expression by miR-21–5p was not through directly targeting at 3′UTR of TIMP3 but through suppressing the expression of TGFβ receptor 2 (TGFBR2). In addition, the knockout of TGFBR2 reduced TIMP3 expression in HUVECs through P38/EGR1 (early growth response protein 1) signaling axis. Moreover, via coculture of ccRCC cell lines with HUVECs and mouse tumor xenograft model, we discovered that the TIMP3 could suppress the proliferation and migration of ccRCC.Implications:Overall, our findings shed new light on the role of hypertension in promoting the progression of ccRCC and provide a potential therapeutic target for patients with ccRCC with hypertension.